The notices it replaced
- Reissues: PAR-22-049 Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)
- 2 steps back: PAR-18-947 Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)
- 3 steps back: PAR-16-166 Integrating Biospecimen Science into Clinical Assay Development (U01)
Who won it before
24 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $8,714,151 in first-year total cost, median $368,144.
Most frequent study sections
- Special Emphasis Panel[ZCA1 RPRB-8 (M2)]3
- Special Emphasis Panel[ZCA1 RPRB-N (J2)]3
- Special Emphasis Panel[ZCA1 RTRB-4 (M1)]2
- Special Emphasis Panel[ZCA1 RTRB-U (J1)]2
- Special Emphasis Panel[ZCA1 SRB-5 (J1)]2
Most frequent institutions
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO3
- SLOAN-KETTERING INST CAN RESEARCH2
- UNIVERSITY OF WASHINGTON2
- BARUCH S. BLUMBERG INSTITUTE1
- BRIGHAM AND WOMEN'S HOSPITAL1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Optimizing pre-analytical variables for reliable mass spectrometry-based quantification of immunomodulatory proteins in cerebrospinal fluid in pediatric neuro-oncology trials1U01CA295226-01 · under PAR-22-049 | PAULOVICH, AMANDA G | FRED HUTCHINSON CANCER CENTER, WA | $440,171 | ZCA1 |
| 2025 | Preanalytical Validation of Circulating Tumor DNA from Surgical Drain Fluid as a marker of Postoperative Minimal Residual Disease in Head and Neck Squamous Cell Carcinoma1U01CA301249-01 · under PAR-22-049 | CHAUDHURI, AADELZEVALLOS, JOSE P. | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $360,643 | ZCA1 |
| 2025 | Impact of preanalytical conditions on functional cancer biomarkers1U01CA288665-01A1 · under PAR-22-049 | BHOLA, PATRICK | HARVARD MEDICAL SCHOOL, MA | $1 | ZCA1 |
| 2024 | MetaboCore: Needle biopsy assay of drug sensitivity for solid tumors.1U01CA281433-01A1 · under PAR-22-049 | WEI, WEIYEUNG, RAYMOND | UNIVERSITY OF WASHINGTON, WA | $401,113 | ZCA1 |
| 2024 | Enrichment for Tumor-derived Cell-free EBV DNA: Towards a Diagnostic Assay for Endemic Burkitt Lymphoma1U01CA271252-01A1 · under PAR-22-049 | AMBINDER, RICHARD FREDERICKXIAN, RENA | JOHNS HOPKINS UNIVERSITY, MD | $357,595 | ZCA1 |
| 2024 | Guidelines for processing and storing liquid biopsy samples for functional assays in research and clinical testing.1U01CA288669-01 · under PAR-22-049 | TOGNON, CRISTINA EVU, TOTHU Q | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $356,850 | ZCA1 |
| 2024 | The impact of oxygen exposure on clinical biomarkers - an underrecognized source of pre-analytic variability1U01CA278865-01A1 · under PAR-22-049 | MILLER, KATHY D.NAKSHATRI, HARIKRISHNA | INDIANA UNIVERSITY INDIANAPOLIS, IN | $355,980 | ZCA1 |
| 2023 | Impact of preanalytic procurement and processing variables on the detection of HCC DNA in urine1U01CA275648-01 · under PAR-22-049 | SU, YING-HSIU | BARUCH S. BLUMBERG INSTITUTE, PA | $395,418 | ZCA1 |
| 2023 | Comprehensive Analysis of Best Practices for Clinical Testing of Malignant Pleural Effusion Specimens1U01CA275514-01A1 · under PAR-22-049 | DEVINE, WALTER PATRICKKHANAFSHAR, ELHAMVAN ZIFFLE, JESSICA | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $369,431 | ZCA1 |
| 2023 | Evaluation of Pre-Analytical Factors of Urine Samples for Urine Cancer Cell Cultures (UCCC) --A Non-Invasive Biomarker – in Monitoring Response and Recurrence of Bladder Cancer1U01CA278927-01 · under PAR-22-049 | LIU, XUEFENG | OHIO STATE UNIVERSITY, OH | $360,281 | ZCA1 |
| 2023 | Advancing the Clinical Translation of Cyst Fluid Assays for Early Detection of Pancreatic Cancer1U01CA271250-01A1 · under PAR-22-049 | KIRKWOOD, KIMBERLY SAUNDERS | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $359,302 | ZCA1 |
| 2022 | Optimization of peripheral blood mononuclear cell (PBMC) processing for robust downstream functional immune cell analysis and correlation with therapeutic efficacy1U01CA267985-01 · under PAR-18-947 | DILLEHAY MCKILLIP, KELSEYWISE-DRAPER, TRISHA M | UNIVERSITY OF CINCINNATI, OH | $353,556 | ZCA1 |
| 2022 | Prostate Needle Biopsies: Impact of Preanalytical Procurement and Processing Variables on the Detection of Gene Expression Signatures of Prostate Cancer Aggressiveness1U01CA271400-01 · under PAR-18-947 | GASTON, SANDRA MPOLLACK, ALANSTOYANOVA, RADKA | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL | $351,131 | ZCA1 |
| 2022 | Evaluation of Patient Factors and Sample Pre-Analytics on Predictive Multiplex Immunohistochemical Assays in Immuno-Oncology Patients1U01CA263986-01A1 · under PAR-18-947 | ROEHRL, MICHAEL H. A. | SLOAN-KETTERING INST CAN RESEARCH, NY | $201,286 | ZCA1 |
| 2021 | Optimization of urinary DNA deep sequencing tests to enhance clinical staging of bladder cancer patients1U01CA260369-01 · under PAR-18-947 | ABBOSH, PHILIP | RESEARCH INST OF FOX CHASE CAN CTR, PA | $422,346 | ZCA1 |
| 2021 | Robust assays to define telomere maintenance mechanisms as cancer biomarkers.1U01CA263988-01 · under PAR-18-947 | REYNOLDS, CHARLES PATRICK | TEXAS TECH UNIVERSITY HEALTH SCIS CENTER, TX | $412,718 | ZCA1 |
| 2021 | Pre-analytical variables of bioanalytes affecting the accuracy of PTCL diagnostic and prognostic genetic signatures1U01CA253218-01A1 · under PAR-18-947 | CHAN, WING C.IQBAL, JAVEEDMURTAZA, MUHAMMED | UNIVERSITY OF NEBRASKA MEDICAL CENTER, NE | $391,146 | ZCA1 |
| 2020 | Liquid biopsy of the lung to profile lung cancer1U01CA253166-01 · under PAR-18-947 | HOUGHTON, A MCGARRYNAIR, VISWAM SIVA | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $427,888 | ZCA1 |
| 2020 | Optimizing pre-analytic sample handling for high throughput TCR sequencing in cutaneous T cell lymphoma1U01CA253190-01 · under PAR-18-947 | CLARK, RACHAEL ANN | BRIGHAM AND WOMEN'S HOSPITAL, MA | $422,791 | ZCA1 |
| 2020 | Influence of Pre-Analytical Factors in Globlastoma MGMT Promoter Methylation Biomarker Assay1U01CA246503-01A1 · under PAR-18-947 | BOMSZTYK, KAROLROSTOMILY, ROBERT C | UNIVERSITY OF WASHINGTON, WA | $414,577 | ZCA1 |
| 2020 | Evaluation of the effect of patient-context factors and sample acquisition on the quality and analytical performance of cell-free DNA and circulating tumor cells profiling assays in prostate cancer pa1U01CA253217-01 · under PAR-18-947 | ARCILA, MARIA ESCHER, HOWARD I | SLOAN-KETTERING INST CAN RESEARCH, NY | $404,888 | ZCA1 |
| 2019 | Pre-analytical factors affecting ctDNA analysis in early and locally advanced breast cancer1U01CA243078-01A1 · under PAR-18-947 | MURTAZA, MUHAMMED | TRANSLATIONAL GENOMICS RESEARCH INST, AZ | $440,008 | ZCA1 |
| 2019 | Mitigation of preanalytic factors influencing brain tumor protein phosphorylation1U01CA229345-01A1 · under PAR-16-166 | PHILLIPS, JOANNA | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $366,857 | ZCA1 |
| 2017 | Integrating Biospecimen Science Into The Development Of RNA-Based Clinical Assays For Patients With Metastatic Breast Cancer1U01CA215547-01 · under PAR-16-166 | SYMMANS, WILLIAM F | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $348,174 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.